British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.
Int J Drug Policy. 2024 Nov;133:104601. doi: 10.1016/j.drugpo.2024.104601. Epub 2024 Oct 7.
In response to the ongoing overdose crisis in Canada, a number of opioid agonist treatment and safer supply programs provide people at high overdose risk with daily-dispensed tablet hydromorphone, with some requiring witnessed ingestion and others providing take-away doses. While these programs are intended to reduce overdose events by limiting people's use of the contaminated drug supply, the experiences of people receiving hydromorphone vary. In this article we explore the ways people repurpose hydromorphone to address unmet needs.
This article draws on in-depth qualitative interviews from two studies evaluating hydromorphone tablet distribution programs in British Columbia, Canada. We used thematic analysis to identify themes related to repurposing hydromorphone. We compared themes across the two studies to identify any similarities or differences in relation to the ways study participants discussed repurposing hydromorphone tablets. We utilize vignettes - snapshots of participant experiences - to analyse and represent the data.
Four vignettes demonstrate how hydromorphone tablets are often being used to address and resolve unmet needs of people who use drugs. While most participants reported reducing their use of illicit drugs, a variety of instrumental uses of tablet hydromorphone were also discussed, including reducing anxiety, addressing sleep issues, withdrawal management, and managing chronic pain.
Our findings demonstrate how people who use drugs are maximizing the benefits of tablet hydromorphone distribution to address unmet needs. Hydromorphone distribution programs represent a public health and harm reduction intervention that is usefully addressing experiences related to structural vulnerabilities (such as inadequate pain management), which are often overlooked amongst stigmatized groups.
为应对加拿大目前的阿片类药物过量危机,一些类阿片激动剂治疗和更安全供应项目为高风险阿片类药物过量人群提供每日分发的氢吗啡酮片剂,有些项目要求现场服用,有些则提供可带走的剂量。虽然这些项目旨在通过限制人们使用受污染的毒品供应来减少过量事件,但接受氢吗啡酮的人的体验各不相同。在本文中,我们探讨了人们重新利用氢吗啡酮来满足未满足需求的方式。
本文借鉴了两项在加拿大不列颠哥伦比亚省评估氢吗啡酮片剂分发项目的深入定性访谈。我们使用主题分析来确定与重新利用氢吗啡酮相关的主题。我们比较了两项研究中的主题,以确定研究参与者在讨论重新利用氢吗啡酮片剂的方式方面存在任何相似或不同之处。我们利用小插曲——参与者经验的快照——来分析和表示数据。
四个小插曲展示了氢吗啡酮片剂如何经常被用于解决和满足吸毒者的未满足需求。虽然大多数参与者报告减少了非法药物的使用,但也讨论了各种工具性用途的氢吗啡酮片剂,包括减轻焦虑、解决睡眠问题、管理戒断症状和管理慢性疼痛。
我们的研究结果表明,吸毒者正在最大限度地利用氢吗啡酮片剂分发来满足未满足的需求。氢吗啡酮分发项目代表了一项公共卫生和减少伤害的干预措施,该干预措施有效地解决了与结构性脆弱性相关的经验,这些经验往往在受污名化的群体中被忽视。